PF-04447943
2 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
2
Ongoing
0
Recruiting
0
Completed
2
Sites
46
Countries
4
Endpoints
48
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 48 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 10 of 48 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
6
4
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT00930059A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease | PF-04447943 Alzheimer’s disease | mild-to-moderate AD | Ph 2 | Completed | 44 | Sep 2010 | - | results |
| NCT00988598A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease | PF-04447943 Alzheimer’s disease | MMSE 18-26 | Ph 1 | Completed | 3 | Jul 2010 | - | results |
Showing 1-2 of 2 trials